MISTIE-III Clinical Trial

Intracerebral hemorrhage (ICH) is a sudden bleeding into brain tissue which can have devastating results.  It is a world-wide problem for which there is currently no effective treatment.  MISTIE III (Minimally Invasive Surgery Plus rt-PA for Intracerebral Hemorrhage Evacuation) is an international, Phase III, 500-patient clinical trial with the primary goal of defining a successful treatment for ICH.  

The MISTIE III intervention seeks to remove blood from the brain through minimally invasive surgery and intermittent dosing of a clot-busting drug, recombinant tissue plasminogen activator (rt-PA).  The hope is that by removing the blood clot faster, injury to the brain will be reduced and the patient’s long-term prognosis will improve. 

 

MISTIE III is the result of over 10 years of preliminary research and clinical trials. An earlier study, MISTIE II, was completed in April 2013. That study suggests that this investigational treatment may offer a possible new treatment for this devastating condition. This next study, MISTIE III, was designed to confirm these preliminary findings. The hope is that the MISTIE approach can improve patient's long-term quality of life. 

 

MISTIE III is funded by the National Institute of Neurological Disorders and Stroke (NINDS), one of the National Institutes of Health. It will involve over 70 centers in the US, Europe and Israel.  

Brain Injury Outcomes

Johns Hopkins University
1550 Orleans Street
CRB-II, 3M50 South
Baltimore, MD 21231 USA
Office:   (410) 614-6996
Fax: (410) 502-7869
 
24-Hr: (410) 736-1368